UnitedHealth Group's shares fell sharply in premarket trading, dropping 12% to $309.30 as investors reacted to unexpected guidance on Medicare Advantage funding from federal regulators.
The Centers for Medicare & Medicaid Services (CMS) said on Monday that Medicare Advantage payment rates for 2027 will increase by 0.09%. That figure was far below analyst forecasts, which had included estimates as high as 6%, and the announcement produced a broad selloff across the managed-care complex.
Competitors were hit hard in the same trading session. Humana fell 15% in premarket trade, while CVS Health declined 12% as market participants re-priced exposure to lower-than-anticipated Medicare funding.
UnitedHealth had reported fourth-quarter adjusted earnings of $2.11 per share, a narrow beat versus the $2.10 per share consensus compiled by LSEG. Despite the slight upside on the top-line earnings metric, market attention centered on the company's rising medical care ratio, which climbed to 88.9% from 85.5% year over year. The increase in the medical care ratio was attributed in the company report to both reduced Medicare funding and higher healthcare utilization.
On an outlook basis, UnitedHealth projected 2026 adjusted earnings per share to exceed $17.75. That projection sits only marginally above the average analyst estimate of $17.74, according to LSEG data, and did not appear sufficient to calm investors worried about the earnings sensitivity to Medicare payment levels.
The stock's drop in 2025 has been pronounced, with shares down roughly 35% this year as the market weighs healthcare cost inflation and regulatory pressures that affect managed-care economics.
Market reaction and context
The CMS decision altered the near-term revenue outlook for Medicare Advantage participants and prompted rapid portfolio adjustments among equity investors focused on the sector. While UnitedHealth posted a modest earnings beat for the quarter, the deterioration in the medical care ratio and an outlook that only narrowly clears analyst consensus left the company vulnerable to a re-rating when durable funding assumptions shift.
What remains uncertain
The CMS rate announcement forms a key variable for profitability across major insurers that participate in Medicare Advantage. How persistent the pressure on medical care ratios will be and whether utilization trends moderate remain open questions based on the information available.
Investors and market watchers will be monitoring subsequent guidance from insurers and any further commentary from CMS, as the industry digests the implications of the 0.09% Medicare Advantage payment rate increase for 2027.